Given that several DPP4i and GLP-1RA have been approved or in clinical development for diabetes and other obesity-related metabolic complications (1, 3–6, 25), in future studies it will be important to confirm that selective pharmacological inhibition of GRK2 mediates the overall actions of GLP-1. Here, GCG is linked to obesity disorder.